anmelden
Novo Nordisk Aktie
41,50
EUR
+1,37
EUR
+3,40
%
41,59
EUR
+1,70
EUR
+4,26
%
Novo Nordisk jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Novo Nordisk Aktie Analyse
| 06.01.22 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.01.22 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 04.01.22 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 04.01.22 | Novo Nordisk Outperform | Bernstein Research | |
| 21.12.21 | Novo Nordisk Hold | Kepler Cheuvreux | |
| 21.12.21 | Novo Nordisk Overweight | Barclays Capital | |
| 20.12.21 | Novo Nordisk Neutral | JP Morgan Chase & Co. | |
| 07.12.21 | Novo Nordisk Buy | Deutsche Bank AG | |
|
Werbung
|
|||
| 07.12.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 29.11.21 | Novo Nordisk Buy | Deutsche Bank AG | |
| 26.11.21 | Novo Nordisk Neutral | UBS AG | |
| 26.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 26.11.21 | Novo Nordisk Outperform | Bernstein Research | |
| 22.11.21 | Novo Nordisk Overweight | Barclays Capital | |
| 19.11.21 | Novo Nordisk Neutral | UBS AG | |
| 18.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.11.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 04.11.21 | Novo Nordisk Overweight | Barclays Capital | |
| 04.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.11.21 | Novo Nordisk Outperform | Bernstein Research | |
| 03.11.21 | Novo Nordisk Neutral | UBS AG | |
| 03.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 01.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 29.10.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 29.10.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 27.10.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 18.10.21 | Novo Nordisk Overweight | Barclays Capital | |
| 14.10.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 28.09.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 14.09.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 02.09.21 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 01.09.21 | Novo Nordisk Buy | Deutsche Bank AG | |
| 26.08.21 | Novo Nordisk Neutral | UBS AG | |
| 23.08.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 20.08.21 | Novo Nordisk Outperform | Bernstein Research | |
| 17.08.21 | Novo Nordisk Neutral | UBS AG | |
| 17.08.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.08.21 | Novo Nordisk Buy | Deutsche Bank AG | |
| 06.08.21 | Novo Nordisk Outperform | Bernstein Research | |
| 06.08.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 05.08.21 | Novo Nordisk Overweight | Barclays Capital | |
| 05.08.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 04.08.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.08.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 04.08.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 29.07.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 19.07.21 | Novo Nordisk Overweight | Barclays Capital | |
| 12.07.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
Werbung
Werbung